Read More

Why Is Rare Neurological Disease Focused Vigil Neuroscience Stock Trading Lower Today?

Vigil Neuroscience Inc (NASDAQ: VIGL) shares are down after the company released interim data from its Phase 2 IGNITE proof-of-concept clinical trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a neurological condition characterized by changes to&nb

VIGL

Read More

FDA Approves Merck’s Blockbuster Cancer Drug For Type Of Gastric Cancer

The FDA has approved Merck & Co Inc's (NYSE: MRK) Keytruda, an anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)

MRK